| Memorandum of Understanding-Investment Related Transactions & Account: FY 2019 |
|
Controller |
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018 |
More Info on Memorandum of Understanding-Investment Related Transactions & Account: FY 2019 |
| Novartis Pharmaceuticals Corporation- Master Clinical Trial Agreements |
|
General Counsel |
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 9/1/1998 through 8/31/2003)
Amendment #1 (extends term: Effective 9/1/2003 through 12/31/2003)
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 1/1/2004 through 12/31/2008)
Amendment #1 (Amended terms regarding Biological Samples) - 4/14/2009
Amendment #2 (Amended terms in 7G Confidential Information) - 11/27/2009
Amendment #3 (Extends term: effective 12/31/2008 to 4/30/2009) - 1/27/2009
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Sponsor Initiated (Eff. 5/1/2009 through 4/30/2014)
Universal Clinical Trial Request Form Template (effective 3/12/2013)
Amendment #1 and HCI/HCP Contract Addendum (effective 6/5/2013)
Amendment #2 (effective 4/30/2014, extending term until 4/30/2019)
Amendment #3 (extending term until 8/31/2023)
Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement - Investigator Initiated (Eff. 11/12/2014 --11/12/2019) |
More Info on Novartis Pharmaceuticals Corporation- Master Clinical Trial Agreements |
| Monthly Financial Report: FY 2019 |
|
Controller |
Jan 2019
Dec 2018
Nov 2018 |
More Info on Monthly Financial Report: FY 2019 |
| Periodic Investment Report FY 2019 |
|
Controller |
FY 2019 May |
More Info on Periodic Investment Report FY 2019 |
| UT System SmartBook |
|
Institutional Research and Analysis |
SmartBook March 2019 |
More Info on UT System SmartBook |
| Procurement - Summary of Purchase Orders |
|
Controller |
Summary Report: 9-1-2015 thru 2-21-2019 |
More Info on Procurement - Summary of Purchase Orders |
| Physician Statement Concerning Tobacco Usage and Fitness to Participate in a Tobacco Cessation Program |
|
Employee Benefits |
Tobacco Cessation Program Physician Statement |
More Info on Physician Statement Concerning Tobacco Usage and Fitness to Participate in a Tobacco Cessation Program |
| Tobacco Premium Program Declaration Form |
|
Employee Benefits |
Tobacco Premium Program Declaration Form |
More Info on Tobacco Premium Program Declaration Form |
| Regeneron Pharmaceuticals, Inc. |
|
General Counsel |
Regeneron Pharmaceuticals, Inc. - Master Clinical Trial Agreement (Effective 2/4/2019 thru 2/4/2024)
Regeneron Pharmaceuticals, Inc. - Master Confidentiality Agreement (Effective 7/5/2018 - 7/5/2028) |
More Info on Regeneron Pharmaceuticals, Inc. |
| Bristol-Myers Squibb |
|
General Counsel |
Master Clinical Trial Agreement - 6/23/1998 (including Amendments #1, #2 and #3)
Master Investigator-Sponsored Research Agreement - 11/5/2018 |
More Info on Bristol-Myers Squibb |
| Clinical Trials Xpress ("CTX") |
|
General Counsel |
Master Confidential Disclosure Agreement (Effective 9/24/2018) |
More Info on Clinical Trials Xpress ("CTX") |
| Contract Processing Checklist |
|
Business Affairs |
Contract Processing Checklist
Questionnaire for Software Purchases or Development
Systemwide Contract Concurrence form |
More Info on Contract Processing Checklist |
| Trip Cancellation Claim Form |
|
Risk Management |
2019 Trip Cancellation Claim Form |
More Info on Trip Cancellation Claim Form |
| Student International Travel Accident & Sickness Policy - Policy Brochure |
|
Risk Management |
UT SITAS 2019 Policy Brochure |
More Info on Student International Travel Accident & Sickness Policy - Policy Brochure |
| Claim Reporting Instructions |
|
Risk Management |
2019 Claim Reporting Instructions |
More Info on Claim Reporting Instructions |
